Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TMO Stock Forecast 2026-2027
$472.80
Current Price
$175.70B
Market Cap
Buy 23
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to TMO Price Targets
+58.6%
To High Target of $750.00
+26.9%
To Median Target of $600.00
+3.6%
To Low Target of $490.00
TMO Price Momentum
-4.0%
1 Week Change
-0.3%
1 Month Change
+17.6%
1 Year Change
-18.4%
Year-to-Date Change
-26.6%
From 52W High of $643.99
+22.7%
From 52W Low of $385.46
📊 TOP ANALYST CALLS
Did TMO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Thermo Fisher is one of their latest high-conviction picks.
Latest TMO Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, TMO has a bullish consensus with a median price target of $600.00 (ranging from $490.00 to $750.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $472.80, the median forecast implies a 26.9% upside. This outlook is supported by 23 Buy, 4 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TMO Analyst Ratings
23
Buy
4
Hold
0
Sell
TMO Price Target Range
Low
$490.00
Average
$600.00
High
$750.00
Current: $472.80
Latest TMO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TMO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 3, 2026 | HSBC | Sidharth Sahoo | Hold | Downgrade | $540.00 |
| Jun 2, 2026 | Wolfe Research | Mike Polark | Outperform | Assumes | $535.00 |
| May 8, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Apr 24, 2026 | Stifel | Buy | Maintains | $N/A | |
| Apr 24, 2026 | Baird | Outperform | Maintains | $N/A | |
| Apr 14, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Apr 6, 2026 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Jan 30, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Jan 30, 2026 | TD Cowen | Buy | Maintains | $N/A | |
| Jan 30, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Jan 9, 2026 | Stifel | Buy | Maintains | $N/A | |
| Jan 7, 2026 | TD Cowen | Buy | Maintains | $N/A | |
| Dec 15, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Dec 11, 2025 | Citigroup | Buy | Upgrade | $N/A | |
| Dec 9, 2025 | Goldman Sachs | Buy | Initiates | $N/A | |
| Dec 8, 2025 | Keybanc | Overweight | Upgrade | $N/A | |
| Dec 2, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Dec 1, 2025 | HSBC | Buy | Upgrade | $N/A | |
| Oct 29, 2025 | Argus Research | Buy | Maintains | $N/A | |
| Oct 28, 2025 | Morgan Stanley | Overweight | Maintains | $N/A |
Thermo Fisher Scientific Inc. (TMO) Competitors
The following stocks are similar to Thermo Fisher based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TMO
Thermo Fisher
mkt cap
175.70B
Thermo Fisher Scientific Inc. (TMO) Financial Data
Thermo Fisher Scientific Inc. has a market capitalization of $175.70B with a P/E ratio of 26.0x. The company generates $45.20B in trailing twelve-month revenue with a 15.2% profit margin.
Revenue growth is +6.2% quarter-over-quarter, while maintaining an operating margin of +17.9% and return on equity of +13.5%.
Valuation Metrics
Market Cap
$175.70B
Enterprise Value
$215.74B
P/E Ratio
26.0x
PEG Ratio
2.3x
Price/Sales
3.9x
Growth & Margins
Revenue Growth (YoY)
+6.2%
Gross Margin
+40.3%
Operating Margin
+17.9%
Net Margin
+15.2%
EPS Growth
+9.6%
Financial Health
Cash/Price Ratio
+1.9%
Current Ratio
1.5x
Debt/Equity
82.9x
ROE
+13.5%
ROA
+5.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Thermo Fisher Scientific Inc. (TMO) Business Model
About Thermo Fisher Scientific Inc.
What They Do
Provides scientific instruments and laboratory equipment.
Business Model
The company operates through four segments: analytical technologies, specialty diagnostic products, life science solutions, and lab products and services. It generates revenue by supplying scientific instruments, laboratory equipment, and consumables to a diverse clientele, including research institutions and pharmaceutical companies, thus facilitating innovation in various scientific fields.
Additional Information
Founded in 2006 and headquartered in Waltham, Massachusetts, the company is crucial in advancing healthcare, pharmaceuticals, biotechnology, and academic research, supporting discoveries and operational efficiencies in life sciences and healthcare markets.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
125,000
CEO
Mr. Marc N. Casper
Country
United States
IPO Year
1987
Website
www.thermofisher.comThermo Fisher Scientific Inc. (TMO) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
ICLR Earnings Reset: What the Accounting Probe Changed
ICON plc details an accounting restatement, flags control weaknesses, and frames 2026 as a reset year amid mix-driven earnings swings.
Jun 05, 2026
By Sridatri Sarkar
Analyst Blog Plus
TransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?
TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jun 04, 2026
By Zacks Equity Research
Realtime BLOG
QuidelOrtho's Respiratory Exposure Remains a Key Near-Term Risk
QDEL's Q1 results show how a milder respiratory season can pressure revenue, margins and cash flow despite stable testing market share.
Jun 03, 2026
By Zacks Equity Research
Analyst Blog Plus
Latest News
Quick Summary
Thermo Fisher Scientific has expanded its Orbitrap mass spectrometry platforms and AI software at the ASMS Conference, aiming to enhance research and biopharma capabilities.
Why It Matters
Thermo Fisher's expansion of its mass spectrometry platforms and AI software enhances its competitive edge in addressing growing market demands, potentially boosting revenue and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Thermo Fisher (TMO) shares rose significantly with above-average trading volume, and recent earnings estimate revisions suggest potential for further price increases.
Why It Matters
Thermo Fisher's rising shares and increased trading volume suggest strong investor confidence. Positive earnings estimate revisions may indicate potential for future price growth.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Thermo Fisher Scientific (NYSE: TMO) will showcase its new mass spectrometers at the ASMS Conference, targeting advanced applications in proteomics, multiomics, biologics, and genetic medicines.
Why It Matters
Thermo Fisher's showcase of advanced mass spectrometers highlights its innovation in biotech, positioning the company for growth in the expanding fields of proteomics and genetic medicine.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Thermo Fisher Scientific Inc. held its Analyst/Investor Day, presenting insights on company strategy, financial performance, and future growth prospects. Further details can be reviewed in the transcript.
Why It Matters
Thermo Fisher's Analyst/Investor Day signals strategic insights and future growth plans, impacting stock valuation and investor confidence in the company’s performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Thermo Fisher Scientific Inc. (NYSE: TMO) announced a quarterly cash dividend of $0.47 per share, payable on July 15, 2026, to shareholders of record by June 15, 2026.
Why It Matters
Thermo Fisher's dividend announcement signals financial stability and commitment to returning value, which can enhance investor confidence and potentially boost stock price.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Thermo Fisher Scientific opened a new bioanalytical and biomarker lab in Gothenburg, Sweden, enhancing global capabilities for drug development support.
Why It Matters
Thermo Fisher's new lab enhances its bioanalytical capabilities, potentially increasing revenue from pharmaceutical clients and strengthening its competitive position in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About TMO Stock
What is Thermo Fisher Scientific Inc.'s (TMO) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Thermo Fisher Scientific Inc. (TMO) has a median price target of $600.00. The highest price target is $750.00 and the lowest is $490.00.
Is TMO stock a good investment in 2026?
According to current analyst ratings, TMO has 23 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $472.80. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TMO stock?
Wall Street analysts predict TMO stock could reach $600.00 in the next 12 months. This represents a 26.9% increase from the current price of $472.80. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Thermo Fisher Scientific Inc.'s business model?
The company operates through four segments: analytical technologies, specialty diagnostic products, life science solutions, and lab products and services. It generates revenue by supplying scientific instruments, laboratory equipment, and consumables to a diverse clientele, including research institutions and pharmaceutical companies, thus facilitating innovation in various scientific fields.
What is the highest forecasted price for TMO Thermo Fisher Scientific Inc.?
The highest price target for TMO is $750.00 from at , which represents a 58.6% increase from the current price of $472.80.
What is the lowest forecasted price for TMO Thermo Fisher Scientific Inc.?
The lowest price target for TMO is $490.00 from at , which represents a 3.6% increase from the current price of $472.80.
What is the overall TMO consensus from analysts for Thermo Fisher Scientific Inc.?
The overall analyst consensus for TMO is bullish. Out of 5 Wall Street analysts, 23 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $600.00.
How accurate are TMO stock price projections?
Stock price projections, including those for Thermo Fisher Scientific Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 7, 2026 10:55 AM UTC